Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc has 133.73M shares outstanding.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc maintains a current ratio of 3.05, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 93.60, indicating elevated leverage, while an interest coverage ratio of 3.24 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc posted a return on equity (ROE) of 100.70, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 15.96, measuring how efficiently the asset base is converted into earnings. The company generates approximately 34.51M in revenue per employee across its workforce of 2,432.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 11.58 indicates how many times Alnylam Pharmaceuticals, Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc recorded an income tax benefit of -147.16M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 13.97B, leaving 14.12B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 20, 2026, Alnylam Pharmaceuticals, Inc's stock has declined approximately 30.96% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc generated 83.94B in revenue and converted that into 14.12B in net income, yielding earnings per share of 102.64. EBITDA reached 18.42B, while operating income came in at 17.47B.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc holds 57.80B in cash and equivalents against 22.14B in total debt, resulting in a net debt position of -12.18B. Total book value stands at 23.66B, with working capital of 54.30B providing operational flexibility.

Alnylam Pharmaceuticals, Inc produced 15.93B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.61B in capital expenditures, free cash flow totaled 14.32B - equivalent to 108.07 per share.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc posted a gross margin of 79.65, reflecting its pricing power and cost economics. The operating margin of 20.81 and net profit margin of 16.82 provide insight into operational efficiency.